| Drug Name |
Cabergoline |
| Drug ID |
BADD_D00329 |
| Description |
Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors. |
| Indications and Usage |
For the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease. |
| Marketing Status |
approved |
| ATC Code |
G02CB03; N04BC06 |
| DrugBank ID |
DB00248
|
| KEGG ID |
D00987
|
| MeSH ID |
D000077465
|
| PubChem ID |
54746
|
| TTD Drug ID |
D04EGX
|
| NDC Product Code |
40016-011; 59762-1005; 47848-009; 14096-153; 23155-823; 70512-860; 50090-5834; 0093-5420; 50742-118 |
| UNII |
LL60K9J05T
|
| Synonyms |
Cabergoline | 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | FCE 21336 | FCE-21336 | Cabaser | Cabaseril | Dostinex | Galastop | Cabergoline Diphosphate | 1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate |
